异甘草酸镁联合丹红注射液治疗病毒性肝炎伴高胆红素血症的临床探讨

目的 探讨异甘草酸镁联合丹红注射液治疗病毒性肝炎伴高胆红素血症的临床疗效.方法 该研究对象为方便选取该院2012年5月―2014年5月收治的120例病毒性肝炎伴高胆红素血症患者,并随机分成对照组(60例)和观察组(60例).对照组采取异甘草酸镁治疗,观察组采取异甘草酸镁联合丹红注射液治疗比较两组患者治疗后的肝功能指标、 血浆凝血酶时间以及治疗总有效率.结果 观察组患者的TBIL、ALT、GGT、PT分别为(37.98±49.95)μmol/L、(70.23±66.83)U/L、(70.26±51.03)U/L和(13.18±1.73)s,治疗总有效率为95.00%,各观察指标数据均显著优于对照组(P<0.05).结论 异甘草酸镁联合丹红注射液治疗病毒性肝炎伴高胆红素血症的临床疗效显著.     

异甘草酸镁注射液治疗急性黄疸型病毒性肝炎临床疗效探讨

目的探讨异甘草酸镁注射液治疗急性黄疸型病毒性肝炎的临床效果。方法从该院2012年6月—2014年3月接收并治疗的急性黄疸型病毒性肝炎患者中选取84例进行回顾性分析,随机分为观察组与对照组,每组42例,对照组行护肝退黄综合治疗,观察组在对照组治疗基础上加用异甘草酸镁注射液治疗,观察两组患者治疗效果、肝功能变化。结果观察组治疗总有效率为92.86%,对照组治疗总有效率为67.65%,观察组治疗效果显著优于对照组;观察组ALT、AST、TBLL指数均明显低于对照组,观察组肝功能情况显著优于对照组,观察组不良反应发生率明显低于对照组,差异有统计学意义（P〈0.05）。结论在急性黄疸型病毒性肝炎的治疗过程中,在常规治疗基础上加用异甘草酸镁能有效提高治疗效果,减少不良反应发生,值得临床应用和推广。     

异甘草酸镁对无黄疸型巨细胞病毒肝炎患儿肝功能、T淋巴细胞亚群及CMV-DNA的影响

  目的  研究异甘草酸镁注射液对无黄疸型巨细胞病毒肝炎患儿肝功能、T淋巴细胞亚群及巨细胞病毒DNA (CMV-DNA)的影响。  方法  选取宁波市妇女儿童医院儿童消化科2017年8月-2020年6月间收治的无黄疸型巨细胞病毒(CMV)肝炎患儿60例, 采用随机数字法将其分为对照组和观察组, 每组30例。对照组患儿静滴还原型谷胱甘肽注射液治疗, 观察组患儿予异甘草酸镁注射液治疗, 均连续治疗2周。比较2组患儿治疗前后肝功能指标、T淋巴细胞亚群及CMV-DNA拷贝数, 同时比较2组患儿不良反应发生率。  结果  治疗后, 观察组外周血ALT、AST及碱性磷酸酶(ALP)水平均明显低于对照组[(48.05±12.53) U/L vs.(72.34±20.60) U/L、(46.90±16.54) U/L vs.(81.35±22.36) U/L、(51.67±13.85) U/L vs.(80.21±16.39) U/L, t=5.518、6.784、7.285, 均P < 0.001], CD3+和CD8+均明显低于对照组(均P < 0.001), CD4+和CD4+/CD8+均明显高于对照组(均P < 0.001), CMV-DNA拷贝数明显低于对照组(P < 0.001);2组患儿的不良反应发生率分别为20.00%、13.33%, 差异无统计学意义(P=0.488)。  结论  异甘草酸镁对无黄疸型CMV肝炎患儿的临床疗效显著, 能改善机体免疫功能, 促进患儿肝功能恢复, 且治疗不良反应少。      

异甘草酸镁联合丹红注射液治疗病毒性肝炎伴高胆红素血症效果探讨

目的：研究分析异甘草酸镁联合丹红注射液治疗病毒性肝炎伴高胆红素血症的临床效果。方法整群选取该院2014年10月—2015年10月期间收治的病毒性肝炎伴高胆红素血症患者78例,将其设定为研究组,再选取同期78例患者设定为参照组,对研究组患者应用异甘草酸镁联合丹红注射液方法治疗,对参照组患者仅应用异甘草酸镁方法治疗,观察两组患者的相关临床指标变化情况。结果对两组患者应用不同治疗方法,研究组患者的血清总胆红素指标(35.5±29.7)umol/L和另外一项丙氨酸氨基转移酶指标(61.2±56.5)U/L与参照组的(75.9±30.2)umol/L和(139.3±54.3) U/L相比,数据差异有统计学意义(P<0.05)。结论对病毒性肝炎伴高胆红素血症患者应用异甘草酸镁联合丹红注射液方法治疗,能够达到预期治疗效果,有利于有效控制患者病情发展。     

灯盏花注射液治疗急性黄疸型病毒性肝炎疗效观察

目的 :观察灯盏花注射液、门冬氨酸钾镁注射液治疗急性黄疸型病毒性肝炎的疗效。方法 :选择 12 0例急性黄疸型病毒性肝炎患者 ,随机分成二组 ,A组为灯盏花组 ,B组为门冬氨酸钾镁组 ,检测治疗前及治疗半月血清总胆红素。结果 :治疗半月时A组血清总胆红素由治疗前的 ( 95 .5 3± 2 5 .47) μmol L下降至 ( 4 4.47± 17.5 2 ) μmol L较B组由治疗前的 ( 96.3 3± 2 4.82 ) μmol L下降至 ( 61.40± 2 2 .19) μmol L疗效显著 (t =-4 .63 8,P <0 .0 0 1)。 结论 :灯盏花注射液对急性黄疸型病毒性肝炎黄疸消退的疗效明显高于门冬氨酸钾镁。     

舒肝宁治疗急性黄疸型病毒性肝炎68例疗效观察

目的:观察舒肝宁注射液治疗急性黄疸型病毒性肝炎的临床疗效。方法:将所选病例随机分成治疗组和对照组,对照组采用基础治疗,治疗组在基础治疗的基础上加用舒肝宁注射液静脉滴注,观察两组的临床疗效。结果:治疗组的疗效和肝功能的改善均优于对照组。结论:舒肝宁注射液治疗急性黄疸型病毒性肝炎,提高了解毒、降酶、退黄的作用。     

异甘草酸镁治疗病毒性肝炎180例临床观察

目的:观察异甘草酸镁注射液治疗各型病毒性肝炎的效果。方法:各型病毒性肝炎359例,分为观察组180例及对照组179例。两组均给予综合性护肝治疗,观察组加用异甘草酸镁注射液150mg每日一次静脉滴注。结果:两组患者中4周内因重症肝炎肝功能衰竭及肝硬化并发症等死亡17例,其中观察组8例,对照组9例,两组差异无统计学意义(P>0.05);存活病例中观察组在临床症状改善、肝功能恢复方面总有效率87.21%,优于对照组60.59%,两组比较差异有统计学意义(P<0.05)。结论:异甘草酸镁注射液可明显改善各型病毒性肝炎患者的临床症状及肝功能。     

异甘草酸镁与甘利欣治疗病毒性肝炎疗效比较

目的通过异甘草酸镁与甘利欣对比，观察异甘草酸镁治疗病毒性肝炎的疗效。方法应用异甘草酸镁治疗病毒性肝炎，并与甘利欣注射液作对照。2组各40例，在同样常规综合治疗的基础上治疗组加用异甘草酸镁100mg，1次／d．对照组加用甘利欣注射液150mg，1次／d。观察项目包括症状、体征及肝功能变化，治疗前后检查血常规、尿常规和肾功能，并随时注意药物不良反应。结果异甘草酸镁组与甘利欣组对降ALT、AST的疗效比较，2组差异有统计学意义（P〈0．01）。结论异甘草酸镁治疗病毒性肝炎在改善症状和降酶方面疗效更佳。     

异甘草酸镁治疗重度戊型黄疸性肝炎患者的疗效观察

目的探讨异甘草酸镁治疗重度戊型黄疸性肝炎患者的疗效。方法选取我院收治的重度戊型黄疸性肝炎患者92例,随机分为观察组和对照组,两组患者均给予常规治疗,同时观察组患者添用异甘草酸镁治疗,对照组给予复方甘草酸苷治疗。结果两组患者治疗后肝功能指标均下降,TBil指标下降观察组明显优于对照组,总有效率观察组显著高于对照组,差异明显(P0.05)。结论异甘草酸镁治疗重度戊性黄疸型肝炎临床效果好,总有效率高,肝功能指标下降明显,无不良反应,值得临床推广应用。     

甘草酸制剂治疗病毒性肝炎疗效观察

目的观察复方甘草酸苷、甘草酸二铵、异甘草酸镁3种甘草酸制剂治疗病毒性肝炎合并高胆红素血症的临床疗效。方法将120例病毒性肝炎合并高胆红素血症患者随机分为A、B、C三组各40例,均接受常规治疗。A组患者加用甘草酸二铵注射液治疗;B组患者加用复方甘草酸苷注射液治疗;C组患者加用异甘草酸镁治疗。均治疗2个月。结果 C组患者肝功能指标及血清纤维化指标均明显低于A、B两组,而B组各项指标又明显低于A组,且组间差异具有统计学意义(P0.05);C组治疗有效率97.50%明显高于A组和B组,而B治疗有效率80.00%又明显高于A组,组间差异具有统计学意义(P0.05)。结论异甘草酸镁在病毒性肝炎合并胆红素血症患者治疗中的应用效果要优于甘草酸二胺及复方甘草酸苷,可以作为临床首选。     

Value of D-Dimers in patients with acute aortic dissection

Objective: To evaluatel the value of D-dimers in patients with acute aortic dissection (AAD). Methods: This study consisted of 16 patients with AAD and 27 non-AAD patients. Serum D-dimets were measured by Sta-Liatest D-DI immunoturbidimetric assay. Results: D-dimer level was higher (P ＜ 0.001) in patients with AAD(7.91 ± 5.52 μg/ml) than that in non- AAD group(1.57±1.24 μg/ml). D-dimer was positive (＞0.4 μg/ml) in all patients with AAD and in 10 control group patients (37%). Among patients with acute AAD, D-dimers tended to be higher in Stanford A than in Stanford B (8.67 ± 4.31 μg/ml vs. 3.24±1.27 μg/ml, P ＜0.01). D-dimer values tended to be higher in more extended disease(3.84 ± 1.65 μg/ml, 8.57 ± 3.58 μg/ml and 11.87 ± 5.69 μg/ml in thoracic aorta, thoracic and abdominal aorta, thoracic and abdominal aorta and iliacal arteries, respectively, P ＜ 0.05 for both 8.57 ± 3.58 and 11.87 ± 5.69 vs. 3.84 ± 1.65 ). Including the control group into the analysis, we found a sensitivity of 100%, a negative predictive value of 100%, and a specificity of 66% and a positive predictive value of 64% for D-dimer in diagnosis of AAD in our patients with suspected AAD. Conclusion: D-dimer was elevated in patients with AAD. A negative D-dimer test result could be useful in excluding AAD.     

Research of combined liver-kidney transplantation model in rats

Objective： To set up a simple and reliable rat model of combined liver-kidney transplantation. Methods： SD rats served as both donors and recipients. 4℃ sodium lactate Ringer＇s was infused from portal veins to donated livers,and from abdominal aorta to donated kidneys, respectively. Anastomosis of the portal vein and the inferior vena cava （IVC） inferior to the right kidney between the graft and the recipient was performed by a double cuff method, then the superior hepatic vena cava with suture. A patch of donated renal artery was anastomosed to the recipient abdominal aorta. The urethra and bile duct were reconstructed with a simple inside bracket. Results： Among 65 cases of combined liver-kidney transplantation, the success rate in the late 40 cases was 77.5%. The function of the grafted liver and kidney remained normal. Conclusion： This rat model of combined liver-kidney transplantation can be established in common laboratory conditions with high success rate and meet the needs of renal transplantation experiment.     

BLOOD PRESSURE CHANGE WITH AGE IN SALT-SENSITIVE TEENAGERS

Objective To observe blood pressure change with age in salt-sensitive teenagers whose salt sensitivity were determined by repeated testing.Methods Salt sensitivity was determined through intravenous infusion of normal saline combined with volume-depletion by oral diuretic furosemide in 55 teenagers. After five years, salt sensitivity was re-examined and subject blood pressure was followed up. Blood pressure changes in salt-sensitive teenagers were compared to that of non-salt sensitive teenagers over five years.Results After 5 years, the repetition rate of salt sensitivity determined by intravenous saline loading is 92.7%. In teenagers with salt sensitivity on the baseline, both the systolic blood pressure increments and increment rates were much higher than non-salt sensitive teenagers (12.7±12.1 mmHg vs. 2.8±5.2 mmHg, P＜ 0.01; 12.2%± 12.0% vs. 2.5% ±4.4%, P＜ 0.001,respectively). There was a similar trend for diastolic blood pressure (8.4 ± 6.4 mmHg vs. 3.7 ± 6.4 mmHg, P = 0.052; 13.2% ±10.6 % vs. 6.8%± 10.1%, P = 0.053, respectively).Conclusions Salt sensitivity determined by intravenous saline loading showed good reproducibility. Blood pressure increments with age were much higher in salt-sensitive teenagers than non-salt sensitive teenagers, especially in terms of systolic blood pressure.     

安心颗粒对急诊经皮冠状动脉介入术后生活质量影响的研究

目的：评价使用安心颗粒对急诊经皮冠状动脉介入术（PPCI）术后生活质量的影响.方法：将160例接受PPCI的急性ST段抬高型心肌梗死患者随机分为安心颗粒组（术前顿服安心颗粒8.8g,术后安心颗粒4.4 g/次,每日2次）和对照组（仅接受基础药物治疗）.所有患者均服用阿司匹林、氯吡格雷和阿托伐他汀.分别在入院时、出院前1d、出院后180 d时,应用心肌梗死多维度量表（MIDAS）、中文版SF-36评价量表对患者生活质量评分.并观察术后30 d以内的出血并发症、血小板减少症发生情况.结果：入院时和出院前1d,两组患者的心肌梗死MIDAS、SF-36量表评分比较无差异（P＞0.05）;出院后180 d时,与对照组比较,安心颗粒组MIDAS、SF-36评分明显减低（P＜0.05）;组内与入院时比较,两组出院前1d、出院后180 d时,MIDAS、SF-36评分均降低（P＜0.05）.两组患者在随访期间均无大量出血、少量出血、重度和极重度血小板减少症发生,安心颗粒组有4例、对照组有7例发生不明显出血（P＞0.05）.两组发生轻度血小板减少症的患者数比较无差异（P＞0.05）.结论：PPCI使用安心颗粒,能改善急性ST段抬高型心肌梗死患者的生活质量,且不增加出血风险.     

The comparative studies of the influences of Urapidil and Nicardipine on sino-atrial node function, atrio-ventricular node function and hemodynamics

Objective:To investigate the influences of urapidil and nicardipine on rabbit sinus function,atrio-ventricular node function and hemodynamics.Methods:Thirty-two Angora's rabbits were selected and randomly divided into four groups.U1 group:urapidil 0.25 mg/kg;U2 group:urapidil 0.5 mg/kg;N1 group:nicardipine 10 μg/kg;N2 group:nicardipine 20 μg/kg.All these medicine were administrated within 30 seconds.Measurements were taken before and after the administration of urapidil or nicardipine for the following data:mean blood pressure(MAP),heart rate(HR),sino-atrial conduction time(SACT),maximal sinoatrial recovery time(SNRTmax)corrected sinus node recovery time(CSNRT),index of sinus node recovery time(SNRTI),Wenckebach A-V conduction frequency (WB),and P-R interval.Results:Significant MAP and HR changes were identified in all of the four groups before and after administration of both urapidil and nicardipine.No significant changes could be found in the rest of the parameters.Intergroup analysis showed that SACT and CSNRT of N1 and N2 groups were shorter than those of the U2 group(P＜0.01);the MAP decreased(P＜0.01)and the HR increased drastically(P＜0.01).Conclusions:Neither urapidil(0.25 mg/kg,0.5 mg/kg)nor nicardipine(10μg/kg,20μg/kg)has any significant influence on rabbit sinus function or rabbit atrio-ventricular node function.Nicardipine could be a better choice than urapidil for parafunctional sinus node patients.     

Expression of OPGmRNA and ODFmRNA in the patients of hip fracture due to osteoporosis

Objective：To investigate the gene expression of osteoprotegerin（OPG） and osteoclast differentiation factor（ODF） in the bone tissue of patients with hip fracture due to osteoporosis. Methods：OPGmRNA and ODFmRNA in the bone tissue in 50 cases of osteoporosis sufferers（over 50 years old） with hip fracture（Observer Group） and 30 cases of hip facture sufferers with no osteoporosis（Control group） were analyzed with the Semi-Quantitative RT-PCR method. Results：The mRNA expressed of ODF, OPG were both high in the patients with hip fracture. In the control group, the expression of OPG mRNA was observed, while the expression of ODF mRNA was very slight. Conclusion：Aged patients contained all signals including OPG, ODF that are essential for inducing osteoclastogenesis and promoting bone resorption.     

The clinicopathological and immuohistochemical analysis of solid-pseudopapillary tumor of the pancreas： report of 9 cases

Objective：To investigate the clinical features, pathological characteristics and immunophenotype of solid-pseudopapillary tumor of the pancreas（SPTP）. Methods：Nine surgically treated cases of SPTP were retrospectively reviewed. Hematoxylin and Eosin（HE） staining and immunohistochemical staining were used to analyze all cases, and the general clinical data was collected. Results：Six patients were asymptomatic except for a palpable mass. Two patients complained of vague-epigastric pain. One patient appeared jaundice. The tumor was encapsulated and solid tissues alternately with cystic tissues. Histologically, the histological structure of solid portion was pseudopapillary with a fibrovascular core. Tumor cells were uniform and medium-sized which were arranged in sheets ets or nests or pseudopapillary patterns. Immunohistochemical studies demonstrated that SPTP proved positive in vimentin（9/9 cases）, AAT（9/9 cases）, NSE（9/9 cases）, ACT（7/9 cases）, CK20（2/9 cases）, CgA（1/9 cases）, S-100（3/gcases）, PR（4/gcases）, Syn（3/9 cases） and CD56（5/9cases）, negative in CEA and ER. Conclusion：SPTP is a tumor predominantly occurring in young women frequently without special symptoms. This tumor has various characteristical histological patterns with different immunophenotype.     

Dynamic Changes in Serum Estradiol and Progesterone levels in Patients of Premenstrual Syndrome with Adverse Flow of Liver-qi

Objective:To probe into the influence of changes of ovarian hormones on the pathogenesis of the specific sub-type premenstrual syndrome(PMS)and reveal partial microcosmic mechanisms of adverse flow of liver-qi.Methods:Estradiol(E2)and progesterone(P)levels in serum were determined at different phases of menstrual cycle by radioimmunoassay.Results:In the group of PMS with adverse flow of liver-qi.the secretive peak value Of E2 and P at the follicular phase significantly decreased,and the secretive peak value at the luteal phase did not come into being.Conclusions:Low E2 and P secretive peak at the follicular phase and absence of secretive peak at the luteal phase is one of the microcosmic mechanisms of PMS with adverse flow of liver-qi.One of the pathophysiologic mechanisms of specific sub-type PMS is probably the continuous low level of E2and P.     

Real-time Three-dimensional Echocardiography in Assessment of Left Ventricular and Right Ventricular Volumes

Real-time three-dimensional echocardiography (RT3DE)is a new ultrasound technique that enables dynamic threedimensional visualization and quantification of the heart in real time. Investigation of feasibility and methodology of RT3DE in determining left ventricular (LV) and right ventricular (RV) volumes, RT3DE was performed in 35 normal adults using Philips SONOS 7500 system with a 2-4 MHz matrix array transducer. The 60°×60° "pyramid" volume database was obtained and analyzed on a TomTec echo workstation. Both LV and RV volumes were calculated with four 3DE methods (i.e. apical 2, 4, 8, and 16-plane) through manually tracing ventricular endocardial borders in end diastole and end systole. Stroke volumes were then calculated. LV volume was also measured by 2DE Simpson's rule using GE VIVID 7 ultrasound machine.     

SCREENING FOR A 21-CHROMOSOME ABNORMALITY IN PREIMPLANTED EMBRYOS OF ELDERLY WOMEN

Increasing maternal age is the only etiological factor unequivocally linked to Down's syndrome in humans. The occurrence rate of newborns with Down's syndrome is about 1/220 in women over 35 years old. However, the occurrence rate in embryos fertilized in vitro, of the elder woman is unclear. Using FISH we screened the number of chromosome 21 in preimplanted embryos of 5 elderly women (average age, 38.4 years) to study the feasibility and necessity of screening trisomy 21 in embryos in patients over 35 years old at the in vitro fertilization (IVF) center.